JP2003530388A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003530388A5 JP2003530388A5 JP2001575563A JP2001575563A JP2003530388A5 JP 2003530388 A5 JP2003530388 A5 JP 2003530388A5 JP 2001575563 A JP2001575563 A JP 2001575563A JP 2001575563 A JP2001575563 A JP 2001575563A JP 2003530388 A5 JP2003530388 A5 JP 2003530388A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylcarbamoyl
- independently
- compound according
- carbamoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 14
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 12
- -1 trifluoromethylthio, trifluoromethylsulfinyl Chemical group 0.000 description 12
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 6
- 125000005236 alkanoylamino group Chemical group 0.000 description 6
- 125000001589 carboacyl group Chemical group 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 4
- 125000004423 acyloxy group Chemical group 0.000 description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 229910052717 sulfur Chemical group 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 3
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 description 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 125000005281 alkyl ureido group Chemical group 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 0 *C(*)(CC1)CCN1II Chemical compound *C(*)(CC1)CCN1II 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021030 Hypomania Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19536500P | 2000-04-06 | 2000-04-06 | |
| US19517700P | 2000-04-06 | 2000-04-06 | |
| US60/195,365 | 2000-04-06 | ||
| US60/195,177 | 2000-04-06 | ||
| GB0008727A GB0008727D0 (en) | 2000-04-11 | 2000-04-11 | Compounds |
| GB0008727.0 | 2000-04-11 | ||
| GB0008728A GB0008728D0 (en) | 2000-04-11 | 2000-04-11 | Compounds |
| GB0008728.8 | 2000-04-11 | ||
| PCT/SE2001/000754 WO2001077089A1 (en) | 2000-04-06 | 2001-04-05 | New neurokinin antagonists for use as medicaments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003530388A JP2003530388A (ja) | 2003-10-14 |
| JP2003530388A5 true JP2003530388A5 (enExample) | 2008-05-29 |
Family
ID=27447827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001575563A Pending JP2003530388A (ja) | 2000-04-06 | 2001-04-05 | 医薬として使用するための新規なニューロキニン拮抗薬 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1276729B1 (enExample) |
| JP (1) | JP2003530388A (enExample) |
| AT (1) | ATE400563T1 (enExample) |
| AU (1) | AU2001246999A1 (enExample) |
| DE (1) | DE60134735D1 (enExample) |
| ES (1) | ES2307605T3 (enExample) |
| WO (1) | WO2001077089A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0003476D0 (sv) * | 2000-09-28 | 2000-09-28 | Astrazeneca Ab | Compounds |
| SE0201938D0 (sv) * | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New process |
| EP1771435A4 (en) * | 2004-06-19 | 2008-02-13 | Human Biomolecular Res Inst | MODULATORS OF NEUROTRANSMITTERS OF THE CENTRAL NERVOUS SYSTEM |
| EP1798226A4 (en) | 2004-08-04 | 2009-06-17 | Taisho Pharmaceutical Co Ltd | TRAIZOL DERIVATIVE |
| RU2409570C2 (ru) | 2006-02-03 | 2011-01-20 | Тайсо Фармасьютикал Ко., Лтд. | Производные триазола |
| WO2007091570A1 (ja) * | 2006-02-06 | 2007-08-16 | Taisho Pharmaceutical Co., Ltd. | スフィンゴシン－１－リン酸結合阻害物質 |
| WO2008090114A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| CN101790517B (zh) | 2007-08-01 | 2013-08-21 | 大正制药株式会社 | 抑制s1p1结合的物质 |
| WO2013004766A1 (en) | 2011-07-04 | 2013-01-10 | Ferrari Giulio | Nk-1 receptor antagonists for treating corneal neovascularisation |
| CA3091944A1 (en) | 2018-02-26 | 2019-08-29 | Ospedale San Raffaele S.R.L. | Nk-1 antagonists for use in the treatment of ocular pain |
| RU2697414C1 (ru) | 2018-05-11 | 2019-08-14 | Общество с ограниченной ответственностью "АЙ БИ ДИ Терапевтикс" | Новый антагонист тахикининовых рецепторов и его применение |
| WO2021180885A1 (en) | 2020-03-11 | 2021-09-16 | Ospedale San Raffaele S.R.L. | Treatment of stem cell deficiency |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9505084D0 (en) * | 1995-03-14 | 1995-05-03 | Pfizer Ltd | Benzamide derivative |
| BR9912013A (pt) * | 1998-07-10 | 2001-04-10 | Astrazeneca Ab | Composto, composição farmacêutica, método de tratar uma condição de doença, e, processo para preparar um composto |
| GB9922519D0 (en) * | 1998-10-07 | 1999-11-24 | Zeneca Ltd | Compounds |
| GB9922521D0 (en) * | 1998-10-07 | 1999-11-24 | Zeneca Ltd | Compounds |
| GB9826941D0 (en) * | 1998-12-09 | 1999-02-03 | Zeneca Pharmaceuticals | Compounds |
| FR2792835B3 (fr) * | 1999-04-27 | 2001-05-25 | Sanofi Sa | Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression |
-
2001
- 2001-04-05 JP JP2001575563A patent/JP2003530388A/ja active Pending
- 2001-04-05 DE DE60134735T patent/DE60134735D1/de not_active Expired - Fee Related
- 2001-04-05 EP EP01920055A patent/EP1276729B1/en not_active Expired - Lifetime
- 2001-04-05 AU AU2001246999A patent/AU2001246999A1/en not_active Abandoned
- 2001-04-05 WO PCT/SE2001/000754 patent/WO2001077089A1/en not_active Ceased
- 2001-04-05 ES ES01920055T patent/ES2307605T3/es not_active Expired - Lifetime
- 2001-04-05 AT AT01920055T patent/ATE400563T1/de not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003530388A5 (enExample) | ||
| JP2004509954A5 (enExample) | ||
| JP2007512299A5 (enExample) | ||
| JP6466348B2 (ja) | スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用 | |
| JP2003511384A5 (enExample) | ||
| JP2007534656A5 (enExample) | ||
| JP2011521911A5 (enExample) | ||
| CA2396824A1 (en) | Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | |
| JP2004509895A5 (enExample) | ||
| JP2005510476A5 (enExample) | ||
| RU2005137403A (ru) | Новые замещенные 3-сера-индолы | |
| JP2002528547A (ja) | 選択的ｃｏｘ‐２インヒビターとしてのピラゾロピリジン誘導体 | |
| JP2002526410A5 (enExample) | ||
| JP2007517044A5 (enExample) | ||
| RU2007101236A (ru) | Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей | |
| JP2014500322A5 (enExample) | ||
| JP2015512435A5 (enExample) | ||
| JP2005527542A5 (enExample) | ||
| JP2008505171A5 (enExample) | ||
| JP2020516671A5 (enExample) | ||
| JP2017532360A5 (enExample) | ||
| JP2018507234A5 (enExample) | ||
| JP2006504738A5 (enExample) | ||
| JP2005522452A5 (enExample) | ||
| EP2247601A1 (en) | Thiazopyrimidinones and uses thereof |